Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Genomic Health, Inc. and Novartis Pharmaceuticals Corporation.

Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™

Release Date: August 31, 2018
Expiration Date: August 31, 2019
Media: Internet - based

Activity Overview

Recent advancements in the understanding of the role of distinct phenotypic and genotypic tumor characteristics have created the potential for oncologists and pathologists to hone management plans and improve patient outcomes. Information on appropriate testing methodology and strategies to best use the results of those tests can help to optimize your clinical decision making. As the volume and pace of emerging clinical trial findings pertaining to actionable treatment targets for your patients continues to increase, this educational activity has been designed to provide the latest information on key topics in pathology that can readily be applied to clinical practice in a variety of settings. This activity is intended to facilitate awareness of recent advancements in the field of cancer pathology and enhance multidisciplinary collaboration. Video commentary from leading clinical experts in oncology and pathology will provide you with their perspectives on critical topics in pathology assessment of malignancies commonly encountered in clinical practice, and the clinical implications of those assessments.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Genomic Health, Inc. and Novartis Pharmaceuticals Corporation.


Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward pathologists and oncologists interested in the management of patients with cancer. Fellows, residents, nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of patients with cancer are also invited to participate.

Learning Objectives

Upon completion of this activity, you should be better prepared to:

  • Identify recent advancements to understand current and emerging biomarkers among commonly encountered malignancies
  • Analyze pathology-associated disparities and variances in care for patients with cancer
  • Apply current clinical evidence and evolving guidelines in cancer pathology to the tailoring of patient testing and treatment protocols
  • Formulate multidisciplinary strategies to optimize cancer diagnosis and management
  • Outline the roles of genomic and targeted assays in management of patients with cancer

Faculty, Staff, and Planners' Disclosures


Alain Borczuk, MD
Professor of Pathology and Laboratory Medicine
Vice Chairman for Anatomic Pathology
Department of Pathology and Laboratory Medicine
Weill Cornell Medicine
New York, NY

Disclosure: No relevant financial relationships with commercial interests to disclose.

Balazs Halmos, MD
Professor of Clinical Medicine
Director, Thoracic/Head & Neck Oncology
Director, Clinical Cancer Genomics
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx, NY

Disclosure: Grant Research Support: Mirati Therapeutics, Eli Lilly, AstraZeneca, Merck, Bristol-Myers Squibb, Boehringer Ingelheim, Novartis, Takeda, Pfizer; Consultant: Foundation One, Guardant Health, AstraZeneca, Pfizer, Boehringer Ingelheim, Eli Lilly, Genentech, Novartis, Takeda, Bristol-Myers Squibb, Novartis

Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT

Disclosure: Grant Research Support: Agensys, AstraZeneca, Bayer, Clovis Oncology, Dendreon, Eli Lilly, Endocyte, Genentech, Innocrin, Johnson & Johnson, Lilly, MedImmune, Medivation, Merck, Millennium, Novartis, Pfizer, Progenics Pharmaceuticals, Roche Laboratories, Sanofi Aventis, Sotio; Consultant: Astellas, AstraZeneca, Bayer, Bellicum Pharmaceuticals, Dendreon, Exelixis, Ferring Pharmaceuticals, Johnson & Johnson, Lilly, Medivation, Millennium, Pfizer, Roche Laboratories, Sanofi Aventis.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By